Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cue Biopharma ( (CUE) ) has shared an update.
On December 19, 2025, Cue Biopharma priced an underwritten public offering of 35,714,286 shares of common stock, or pre-funded warrants in lieu of shares, together with accompanying common stock warrants to purchase 17,857,143 shares, at a combined price of $0.28 per share-and-warrant unit (or $0.279 for units with pre-funded warrants), for expected gross proceeds of about $10 million before fees and expenses. All securities in the deal are being sold by the company, with H.C. Wainwright & Co. acting as sole bookrunner and Newbridge Securities as co-manager, and the underwriters have been granted a 30-day option to purchase up to an additional 5,357,140 shares and/or 2,678,570 warrants; the offering, expected to close around December 22, 2025, is projected, together with existing cash, marketable securities and payments from its ImmunoScape collaboration, to fund Cue Biopharma’s operations into the first quarter of 2027, extending its cash runway and potentially alleviating near-term financing pressure for stakeholders despite the dilutive impact of the equity and warrant issuance.
The most recent analyst rating on (CUE) stock is a Sell with a $0.32 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.
Spark’s Take on CUE Stock
According to Spark, TipRanks’ AI Analyst, CUE is a Underperform.
Cue Biopharma’s overall stock score is heavily impacted by its poor financial performance and negative technical indicators. Despite positive corporate events, these factors are not enough to offset the significant financial and technical challenges.
To see Spark’s full report on CUE stock, click here.
More about Cue Biopharma
Cue Biopharma is a Boston-based, clinical-stage biopharmaceutical company developing a novel class of injectable biologic therapies designed to selectively engage and modulate disease-specific T cells within the body. Leveraging its proprietary Immuno-STAT platform, the company focuses on harnessing the immune system’s therapeutic potential for autoimmune diseases while aiming to avoid the adverse effects associated with broad systemic immune modulation.
Average Trading Volume: 322,313
Technical Sentiment Signal: Sell
Current Market Cap: $31.5M
See more insights into CUE stock on TipRanks’ Stock Analysis page.